AASLD 2026三项代谢相关脂肪性肝病研究进展:生物标志物预测、GLP‑1RA与纤维化趋势及J2H‑1702 IIa期初步结果
AASLD 2026 | 代谢相关脂肪性肝病领域热点研究
AASLD 2026大会报道三项代谢相关脂肪性肝病(MASLD/MASH)研究。其一基于MAESTRO‑NASHⅢ期试验亚组分析,显示瑞美替罗治疗第12、24、52周ALT下降≥20%及MRI‑PDFF下降可显著预测肝活检证实的MASH缓解与纤维化改善。
报道AASLD 2026三项代谢相关脂肪性肝病研究,涵盖瑞美替罗无创标志物预测价值、GLP‑1RA时代纤维化与炎症脱钩趋势及早期IIa期试验初步数据。
2026年11月5日-9日,全球肝病领域顶级学术盛会-The Liver Meeting 2026 (AASLD 2026)在美国•丹佛召开。本届大会汇聚来自世界各地的肝病临床专家与基础研究学者,围绕病毒性肝炎、代谢功能障碍相关脂肪性肝病、肝硬化及其并发症、肝癌、肝移植和肝病基础研究等领域,集中展示前沿研究成果与临床诊疗新进展。
为助力广大读者精准捕捉会议的学术精髓,及时洞悉领域前沿动态,肝胆相照平台特别甄选会议摘要中的热点研究内容,本篇专题报道将聚焦“代谢相关脂肪性肝病”这一关键领域,为广大同仁提供最新研究进展,展望其在临床实践中的广阔应用前景。
一 摘要编号:0010
瑞美替罗治疗MASH期间早期及第52周无创标志物变化预测组织学缓解与纤维化改善
EARLY AND WEEK 52 BIOMARKER (MRI-PDFF, ALT, MRE AND PRO-C3) RESPONSES TO RESMETIROM PREDICT IMPROVEMENTS IN MASH AND LIVER FIBROSIS
作者:Rohit Loomba1 Rebecca Taub2 Krishna Padmanabhan2 Dominic Labriola2 Mazen Noureddin3 Naim Alkhouri4
1 San Diego School of Medicine
2 Madrigal Pharmaceuticals
3 Houston Methodist Hospital
4 Summit Clinical Research
背景
MAESTRO-NASH 研究(NCT03900429)为一项正在开展、周期 54个月的随机、双盲、安慰剂对照Ⅲ期临床试验,评估瑞美替罗(resmetirom,RES)用于合并F2/F3期纤维化的代谢功能障碍相关脂肪性肝炎(MASH)患者的治疗效果。该研究既往公布的52周肝组织学结果证实,80 mg与 100 mg剂量的瑞美替罗可实现MASH缓解及纤维化改善,为该药物获批提供了依据。本分析旨在报告早期无创生物标志物的动态变化、其与第52周肝活检应答的相关性,以及接受治疗患者获得早期标志物应答的发生概率。
Background:MAESTRO-NASH (NCT03900429) is an ongoing 54-month, randomized, double-blind, placebo (PBO)-controlled Phase 3 trial evaluating the efficacy of resmetirom (RES) in patients with MASH and F2/F3 fibrosis. The 52-week histologic endpoints demonstratted resolution of MASH (MR) and fibrosis improvement (FI) with RES 80 mg and 100 mg leading to approval. We report early non-invasive biomarkers of change and their correlation with Week (W) 52 biopsy responses, as well as the odds of achieving an early biomarker response with treatment.
方法
为探究早期生物标志物应答与第52周肝活检结局的关联,本研究分析瑞美替罗或安慰剂治疗后第12、24、52周丙氨酸氨基转移酶(ALT)、磁共振弹性成像(MRE)、MRI 质子密度脂肪分数(MRI-PDFF)的变化,及其与组织学定义的MASH缓解(MR)和纤维化改善(FI)之间的关系;针对MRE与MRI-PDFF的重点分析额外纳入第16周时间点。研究计算不同治疗组达到早期生物标志物改善的优势比,并采用 Ⅲ 型前胶原N端肽(PRO-C3)的变化反映治疗应答。
Methods: To assess relationships between early biomarker responses and W52 liver biopsy outcomes, changes in ALT, MRE, MRIPDFF, at W12,24 52 following initiation of RES or PBO were analyzed for correlation with biopsy-defined MR and FI. Odds of achieving early improvement in these biomarkers were evaluated as a function of treatment. PRO-C3 change was a measure of response.
结果
治疗第12、24、52周ALT下降≥20%,均与第52周更高概率的 MASH 缓解及纤维化改善相关。在瑞美替罗组中,ALT应答对应上述终点的优势比依次为2.0、2.2和2.6(均 P<0.002);与安慰剂相比,瑞美替罗组在第12、24、52周获得与纤维化改善相关 ALT应答的优势比分别为2.2、2.7 和 3.6(均 P<0.001),MASH 缓解方面的趋势与之相近。第16周和第52周MRE下降≥15%,与第52周纤维化改善、MASH 缓解的发生概率升高相关。瑞美替罗组MRE应答预测纤维化改善的优势比分别为2.6和2.3(P≤0.02),安慰剂组该关联较弱;MASH 缓解的结果模式类似。
相较于安慰剂,瑞美替罗组第52周出现 MRE 应答的概率显著更高(OR=1.71),但第 16 周组间差异无统计学意义(OR=1.31)。第 16 周和第 52 周 MRI-PDFF 较基线下降≥30%,与纤维化改善及 MASH 缓解呈强相关。瑞美替罗组 MRI-PDFF 应答对应纤维化改善的优势比分别为1.9和2.95(P≤0.02),对应第52周MASH缓解的优势比约为6.5。
与安慰剂相比,瑞美替罗组第16周、第52周达到MRI-PDFF应答的优势比分别为12.4和6.7(均 P<0.0001)。在F3期纤维化患者中,第24周及第52周PRO-C3 的绝对值变化与百分比变化均和纤维化改善相关。第52周时,80 mg 剂量组纤维化改善无应答者与应答者的PRO-C3变化分别为-7%和-23%;100 mg 剂量组分别为-14%和-20%;安慰剂组分别为0%和-20%。瑞美替罗组纤维化改善应答者占比更高;瑞美替罗组与安慰剂组回归曲线对应的P值分别为0.0017和0.04。
Results:≥20% reduction in ALT at w12, 24, 52 was associated with higher odds (OR) of W52 MR/FI. With RES, ALT response showed an OR of 2.0, 2.2, 2.6 repectively at W12, 24, 52; p < 0.002). RES OR of achieving an FI response at w12, 24 and 52, compared to PBO: ORs of 2.2, 2.7, 3.6 respectively. All p < 0.001. MR was similar. ≥15% reduction in MRE at W16, 52 was associated with higher OR of Week 52 FI/MR. With RES, MRE response ORs FI, 2.6 and 2.3 at W16, 52, respectively, p ≤0.02, less association in PBO. MR was similar. RES compared with PBO stat sig. odds of achieving an MRE response, at W52 (OR = 1.71) but not at (W16 OR = 1.31). A ≥30% reduction in MRI-PDFF from baseline at W16 and 52 was strongly associated with higher odds of FI and MR. With RES, MRI-PDFF response was associated with increased odds of FI (ORs 1.9 and 2.95 at w16 and 52, respectively; p ≤0.02) and MR at Week 52 (OR ~ 6.5). RES was associated with significantly higher odds of achieving an PDFF response compared with PBO at W16, 52 (ORs 12.4 and 6.7; both p < 0.0001). For Pro-C3, change and % change n PRO-C3 at Weeks 24 and 52 in F3 showed a relationship to FI in all treatment groups, w52: 80 mg, -7%, -23%; 100 mg, -14%, -20%; PBO, 0%, -20% FI nonresponders and responders, respectively with far more responders in RES, regression currve p = 0.0017 RES, p = 0.04 PBO.
结论
瑞美替罗治疗早期及第52周的生物标志物应答,尤其是第16周和第52周MRI-PDFF的下降,与肝活检证实的纤维化改善及MASH缓解相关。ALT、MRE 和PRO-C3 在第24周或第52周前后的下降,同样与瑞美替罗治疗后肝活检提示的纤维化改善显著相关。
Conclusion:Early and W52 responses to RES, particularly reduction in PDFF at W16 and W52, correlate with FI and MR responses on liver biopsy. Reduction in ALT, MRE and PRO-C3 ( ≤W24 and W52) showed a significant correlation with FI on biopsy with RES treatment.
二 摘要编号:0005
GLP-1受体激动剂时代MASH疾病活动度与纤维化脱钩:当代肝活检队列研究
DECOUPLING OF DISEASE ACTIVITY AND FIBROSIS IN MASH: INSIGHTS FROM CONTEMPORARY BIOPSY COHORTS IN THE GLP-1 RECEPTOR AGONIST ERA
作者:Winston Dunn1 Gražina Binkauskiene2 Elizabeth Brombosz2 Rashmee Patil3 Rohit Puskoor4 David Huang5 Nirupama Esther Jerome4 John Poulos6 Alaa Abousaif7 Aasim Sheikh8 Alma Laura Ladrón de Guevara9 Marcelo Kugelmas10 Mousab Tabbaa11 Sam Moussa12 Vlad Ratziu13 Meena Bansal14 Jörn Schattenberg15 Mazen Noureddin16 Naim Alkhouri17
1 University of Kansas Medical Center
2 Summit Clinical Research Solutions
3 Pinnacle at San Antonio, Summit Clinical Research Solutions
4 Pinnacle at Austin, Summit Clinical Research Solutions
5 Houston Research Institute – Main
6 Coastal Research Institute
7 Providence St. Joseph Hospital-Orange
8 GI Specialists of Georgia
9 Centro De Investigacion Y Gastroenterologia
10 South Denver Gastroenterology
11 Clinical Research Institute of Ohio
12 Adobe Clinical Research
13 Service D' Hepatogastroenterologie (FR)
14 Icahn School of Medicine at Mount Sinai (ISMMS)
15 Saarland University Medical Center
16 Houston Methodist Hospital, Houston Research Institute, Summit Clinical Research Solutions
17 Summit Clinical Research
背景
GLP1受体激动剂(GLP1RA)在代谢功能障碍相关脂肪性肝炎(MASH)患者中的应用日趋广泛,但该药与真实世界肝组织学特征之间的关联仍不明确。本研究旨在分析近年参加 MASH 临床试验筛查人群的肝纤维化严重程度与组织学活动度的时间变化趋势,并探讨 GLP1RA用药情况与肝活检结果的关联。
Background:GLP-1 receptor agonists (RAs) are increasingly used in MASH, yet their association with liver histology in real-world biopsy cohorts remains incompletely characterized. We evaluated temporal trends in fibrosis severity and histologic activity among patients enrolled in contemporary MASH clinical trials and assessed the relationship between GLP-1RA use and biopsy findings.
方法
本研究汇总2019—2025年纳入非肝硬化MASH临床试验筛查受试者的肝活检数据;排除专门针对肝硬化人群的试验,以降低选择偏倚。组织学终点包括NAFLD活动度评分(NAS)及其各项组分。采用logistic 回归与线性回归分析时间趋势;校正模型纳入GLP1RA既往暴露、当前用药状态、糖尿病、体重指数及活检年份,评估上述因素与纤维化分期、NAS的相关性。
Methods:We analyzed pooled biopsy data from patients screened for non-cirrhotic MASH clinical trials between 2019 and 2025. Cirrhosisfocused trials were excluded to reduce selection bias. Histologic outcomes included NAS and its individual components. Temporal trends were assessed using logistic and linear regression models. GLP-1RA exposure, ongoing GLP-1RA use, diabetes, BMI, and biopsy year were evaluated in adjusted models examining associations with fibrosis and NAS.
结果
在具备活检时间及纤维化分期资料的7819例患者中,进展期纤维化占比随时间显著升高:F4期比例由2019-2020年的 3.1% 上升至 2025 年的 13.2%,F3/F4 期由 22.1% 升至 41.4%,F2 期及以上由 43.0% 升至 76.0%(均 P<0.0001)。
与之相反,组织学疾病活动度呈改善趋势,平均 NAS 由 4.12 下降至 3.03,估算每年降低 0.259 分(P<0.0001);重度脂肪变性比例由 27.4% 降至 10.4%,肝细胞气球样变由 21.8% 降至 11.9%,高分小叶炎症的占比同样下降。GLP-1RA 使用率由 2023 年的 7.8% 上升至 2025 年的 10.3%(总用药者 n=553);在该用药人群中,同期 F4 期比例由 7.7% 增至 31.4%,F3/F4 期由 28.6% 升至 55.2%。Logistic 回归模型证实,F4 期纤维化的发生优势逐年升高(OR=2.07 / 年,P<0.0001)。
未校正分析显示,GLP1RA 使用者的纤维化程度重于未使用者:F3/F4 占比分别为 69.8% 和 41.6%,F4 占比分别为 32.5% 和 21.0%(均 P<0.0001)。但在校正活检年份、BMI 与糖尿病因素后,GLP1RA 使用与更低的 NAS 相关(效应估计值−0.186,P=0.01);当前正在用药者结果一致(−0.222,P=0.005)。GLP1RA 使用者合并糖尿病的比例更高(57.7% 对比 37.3%)。
Results: Among 7,819 patients with available biopsy date and fibrosis staging, advanced fibrosis increased substantially over time. F4 increased from 3.1% in 2019–2020 to 13.2% in 2025, while F3/F4 increased from 22.1% to 41.4%, and F2+ from 43.0% to 76.0% (all p < 0.0001). In contrast, histologic activity improved over time: mean NAS decreased from 4.12 to 3.03 (estimate −0.259/year, p < 0.0001). Severe steatosis declined from 27.4% to 10.4%, ballooning decreased from 21.8% to 11.9%, and higher lobular inflammation scores also declined over time. GLP-1RA use increased from 7.8% in 2023 to 10.3% in 2025 (total n = 553). During the same period, F4 prevalence increased from 7.7% to 31.4%, while F3/F4 fibrosis increased from 28.6% to 55.2%. Logistic models confirmed increasing odds of F4 fibrosis over time (OR 2.07/year, p < 0.0001). GLP1RA users had greater unadjusted fibrosis severity than non-users (F3/F4: 69.8% vs 41.6%; F4: 32.5% vs 21.0%; both p < 0.0001). However, after adjustment for biopsy year, BMI, and diabetes, GLP-1RA use was associated with lower NAS (estimate −0.186, p = 0.01), with similar findings for ongoing GLP-1RA use (estimate −0.222, p = 0.005). Diabetes was more common among GLP-1RA users (57.7% vs 37.3%).
结论
在当前 MASH 临床试验筛查人群中,尽管脂肪变性、炎症相关的组织学活动度有所改善,纤维化严重程度却随时间明显加重。经校正混杂因素后,GLP1RA 用药与更低的 NAS 相关,提示坏死性炎症活动可得到改善,但并未观察到纤维化程度下降。GLP1RA 使用者基线纤维化负荷更高,可能受糖尿病、代谢危险因素、转诊模式以及纤维化逆转所需时间不足等混杂因素影响。上述结果提示,MASH 短期炎症活动改善与长期纤维化进展结局可能并不一致。
Conclusion:In contemporary MASH clinical trial populations, fibrosis severity increased markedly over time despite improvement in inflammatory and steatotic histologic features. Increasing GLP-1RA use was associated with lower adjusted NAS, suggesting improved necroinflammatory activity, but not with reduced fibrosis severity. The higher fibrosis burden observed among GLP-1RA users likely reflects confounding by diabetes, metabolic risk, referral patterns, and insufficient duration for fibrosis regression. These findings highlight a potential divergence between short-term improvements in disease activity and longer-term fibrosis outcomes in modern MASH populations.
三 摘要编号:3533
选择性11β-HSD1抑制剂J2H-1702治疗MASLD的多中心随机IIa期临床试验
SAFETY AND EFFICACY OF J2H-1702, A NOVEL 11b-HSD1 INHIBITOR, IN MASLD: A PHASE 2A RANDOMIZED CONTROLLED TRIAL
作者:Dae Won Jun1 Joo Hyun Oh2 Hyun Chin Cho3 Eileen Yoon4 Gi-Ae Kim5
1 Department of Gastroenterology, Hanyang University
2 Department of Gastroenterology, CHA University College of Medicine, Bundang, Korea
3 Department of Internal Medicine, Gyeongsang National University
4 Department of Gastroenterology, Hanyang University College of Medicine
5 Department of Internal Medicine, Kyung Hee University
背景
由 11β羟类固醇脱氢酶 1 型(11βHSD1)介导的肝内糖皮质激素过量,是促进肝脂肪变性与代谢功能紊乱的明确机制。新型选择性 11βHSD1 抑制剂 J2H1702 在临床前模型中展现出良好的代谢调节及抗纤维化活性。本研究旨在评估 J2H1702 治疗代谢功能障碍相关脂肪性肝病(MASLD)的疗效与安全性。
Background:Intrahepatic glucocorticoid excess, mediated by 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), is a validated mechanism driving hepatic steatosis and metabolic dysfunction. J2H-1702, a novel selective 11βHSD1 inhibitor, demonstrated favorable metabolic and antifibrotic effects in preclinical models. We evaluated the efficacy and safety of J2H-1702 in patients with metabolic dysfunction-associated steatotic liver disease (MASLD).
方法
本研究为一项多中心、随机、双盲、安慰剂对照试验,共纳入 87 例 MASLD患者,按照 1∶1∶1∶1 的比例随机分组,分别接受每日口服 J2H1702 50 mg、100 mg、200 mg或安慰剂,持续治疗 12 周。MASLD 入组标准要求 MRIPDFF≥8% 且磁共振弹性成像(MRE)≥2.5 kPa。共同主要终点为第 12 周 MRIPDFF 检测的肝脏脂肪含量百分比变化,以及 MRE 检测的肝脏硬度变化。
Methods:In this multicenter, randomized, double-blind, and placebo-controlled trial, 87 patients with MASLD were randomly assigned to oral administration of J2H-1702 50 mg, 100 mg, 200 mg, or placebo once daily for 12 weeks in a 1:1:1:1 ratio. MASLD was defined as magnetic resonance imaging-proton density fat fraction (MRI-PDFF) ≥8% and magnetic resonance elastography (MRE) ≥2.5 kPa. Coprimary endpoints were percent change in hepatic fat by MRI-PDFF and hepatic stiffness by MRE at week 12.
结果
全部 87 例患者均纳入完整分析集,其中50mg 组、100mg组、200 mg组各22例,安慰剂组21例。治疗第12周,J2H1702可降低肝脏脂肪含量,尤以200 mg剂量效应显著(相对基线变化−18.7%,安慰剂组为+3.1%;最小二乘均数差值−22.3%,P=0.011);同时肝酶、体重及低密度脂蛋白胆固醇水平得到改善。MRE 测得的肝脏硬度未见显著改变。研究期间发生的不良事件以轻度为主,各组不良事件发生率相近。促肾上腺皮质激素与脱氢表雄酮水平呈一过性升高,符合药物抑制 11βHSD1 的作用机制,停药后可恢复。
Results:All 87 patients were included in the full analysis set (50 mg, n=22; 100 mg, n=22; 200 mg, n=22; placebo, n=21). At week 12, J2H-1702, especially 200 mg, produced a significant reduction in hepatic fat by MRI-PDFF (−18.7% vs. +3.1%; LS mean difference, −22.3%; p=0.011), alongside improvements in liver enzymes, body weight, and lowdensity lipoprotein cholesterol. No significant change in hepatic stiffness by MRE was observed. Treatmentemergent adverse events were mild and comparable across groups. Increases in adrenocorticotropic hormone and dehydroepiandrosterone, consistent with on-target 11βHSD1 inhibition, were transient and resolved after treatment discontinuation.
结论
这项探索性 Ⅱa 期研究表明,J2H-1702 治疗 12 周能够减轻 MASLD 患者的肝脂肪变性,并改善肝酶及心脏代谢相关指标,总体安全性尚可,支持后续进一步开展临床研究。
Conclusion:In this exploratory phase 2a study, J2H-1702 showed a reduction in hepatic steatosis, liver enzymes, and cardiometabolic parameters with a favorable safety profile in patients with MASLD over 12 weeks, supporting further clinical development.
版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
来源:梅斯医学·临床资讯 · news.medsci.cn